CCT301-38

N/A

Report date: 2025/01/02 16:11:22

Base Information

Drug NameCCT301-38
Drug Alias NameCCT301-38 AXLCCT301-38CCT3-AXL-0038
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAXL receptor tyrosine kinase inhibitors
TargetsAXL receptor tyrosine kinase
Therapy Area/IndicationsRhinitis, Allergic, SeasonalCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesBioAtla Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Sinobioway Sunterra BiotechExuma Biotech Corp
Active IndicationsN/A
Inactive IndicationsRhinitis, Allergic, SeasonalCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A